Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Payables: 2012-2025

Historic Payables for CorMedix (CRMD) over the last 11 years, with Sep 2025 value amounting to $20.5 million.

  • CorMedix's Payables rose 1422.09% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year increase of 202.22%. This contributed to the annual value of $1.7 million for FY2024, which is N/A change from last year.
  • Per CorMedix's latest filing, its Payables stood at $20.5 million for Q3 2025, which was up 251.73% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Payables ranged from a high of $20.5 million in Q3 2025 and a low of $943,344 during Q2 2021.
  • In the last 3 years, CorMedix's Payables had a median value of $2.6 million in 2023 and averaged $4.4 million.
  • Per our database at Business Quant, CorMedix's Payables crashed by 60.69% in 2021 and then skyrocketed by 1,422.09% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Payables stood at $2.2 million in 2021, then declined by 0.34% to $2.2 million in 2022, then surged by 35.01% to $2.4 million in 2023, then crashed by 43.68% to $1.7 million in 2024, then skyrocketed by 1,422.09% to $20.5 million in 2025.
  • Its last three reported values are $20.5 million in Q3 2025, $5.8 million for Q2 2025, and $1.9 million during Q1 2025.